Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in IDEAYA Biosciences, Inc. or Zai Lab Limited because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how IDEAYA Biosciences, Inc. and Zai Lab Limited compare based on key financial metrics to determine which better meets your investment needs.

About IDEAYA Biosciences, Inc. and Zai Lab Limited

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Latest Biotechnology and IDEAYA Biosciences, Inc., Zai Lab Limited Stock News

As of May 7, 2026, IDEAYA Biosciences, Inc. had a $2.5 billion market capitalization, compared to the Biotechnology median of $275.8 million. IDEAYA Biosciences, Inc.’s stock is down 18.2% in 2026, up 0.4% in the previous five trading days and up 59.1% in the past year.

Currently, IDEAYA Biosciences, Inc. does not have a price-earnings ratio. IDEAYA Biosciences, Inc.’s trailing 12-month revenue is $225.3 million with a -62.2% net profit margin. As of May 7, 2026, IDEAYA Biosciences, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.349 per share for the current fiscal year. IDEAYA Biosciences, Inc. does not currently pay a dividend.

As of May 7, 2026, Zai Lab Limited had a $2.2 billion market cap, putting it in the 56th percentile of all stocks. Zai Lab Limited’s stock is up 5.7% in 2026, down 13.4% in the previous five trading days and down 32.73% in the past year.

Currently, Zai Lab Limited does not have a price-earnings ratio. Zai Lab Limited’s trailing 12-month revenue is $460.2 million with a -38.1% net profit margin. Year-over-year quarterly sales growth most recently was 17.0%. Analysts expect adjusted earnings to reach $-2.009 per share for the current fiscal year. Zai Lab Limited does not currently pay a dividend.

How We Compare IDEAYA Biosciences, Inc. and Zai Lab Limited Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at IDEAYA Biosciences, Inc. and Zai Lab Limited’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

IDEAYA Biosciences, Inc. and Zai Lab Limited Stock Value Grades

Company	Ticker	Value
IDEAYA Biosciences, Inc.	IDYA	F
Zai Lab Limited	ZLAB	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

IDEAYA Biosciences, Inc. has a Value Score of 20, which is Ultra Expensive. Zai Lab Limited has a Value Score of 16, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither IDEAYA Biosciences, Inc. or Zai Lab Limited has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if IDEAYA Biosciences, Inc. or Zai Lab Limited is the better investment when it comes to value.

IDEAYA Biosciences, Inc. and Zai Lab Limited Growth Grades

Company	Ticker	Growth
IDEAYA Biosciences, Inc.	IDYA	F
Zai Lab Limited	ZLAB	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

IDEAYA Biosciences, Inc. has a Growth Score of 12, which is Very Weak. Zai Lab Limited has a Growth Score of 29, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither IDEAYA Biosciences, Inc. or Zai Lab Limited has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if IDEAYA Biosciences, Inc. or Zai Lab Limited is the better investment when it comes to sustainable growth.

IDEAYA Biosciences, Inc. and Zai Lab Limited’s Quality Grades

Company	Ticker	Quality
IDEAYA Biosciences, Inc.	IDYA	D
Zai Lab Limited	ZLAB	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

IDEAYA Biosciences, Inc. has a Quality Score of 39, which is Weak. Zai Lab Limited has a Quality Score of 12, which is Very Weak.

The Quality Stock Winner: No Clear Winner

Neither IDEAYA Biosciences, Inc. or Zai Lab Limited has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if IDEAYA Biosciences, Inc. or Zai Lab Limited is the better investment when it comes to quality.

Other IDEAYA Biosciences, Inc. and Zai Lab Limited Grades

In addition to Quality, Growth and Value, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether IDEAYA Biosciences, Inc. and Zai Lab Limited pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, IDEAYA Biosciences, Inc. or Zai Lab Limited Stock?

Overall, IDEAYA Biosciences, Inc. stock has a Value Score of 20, Growth Score of 12 and Quality Score of 39.

Zai Lab Limited stock has a Value Score of 16, Growth Score of 29 and Quality Score of 12.

Comparing IDEAYA Biosciences, Inc. and Zai Lab Limited’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.